Intelligence Feed event · Equity · 2026-10-04

    Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer

    Question

    Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer

    Direct answer

    Platinum-resistant ovarian cancer represents a difficult oncology indication with limited standard-of-care options. An ORR of 45.9% combined with a 9.5-month median PFS establishes competitive efficacy for Genmab's topoisomerase I ADC platform. These clinical results provide regulatory derisking ahead of potential pivotal Phase 3 study designs and commercial partnering discussions.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-rina-s-adc-delivers-45-9-response-rate-in-platinum-resistant-ovarian-canc-21f2cc

    EQUITY
    Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
    Platinum-resistant ovarian cancer represents a difficult oncology indication with limited standard-of-care options. An ORR of 45.9% combined with a 9.5-month median PFS establishes competitive efficacy for Genmab's topoisomerase I ADC platform. These clinical results provide regulatory derisking ahead of potential pivotal Phase 3 study designs and commercial partnering discussions.
    GMAB
    Impact
    70
    OCT 4
    SIG
    90%
    GMAB
    Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
    Platinum-resistant ovarian cancer represents a difficult oncology indication with limited standard-of-care options. An ORR of 45.9% combined with a 9.5-month median PFS establishes competitive efficacy for Genmab's topoisomerase I ADC platform. These clinical results provide regulatory derisking ahead of potential pivotal Phase 3 study designs and commercial partnering discussions.
    → A 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer improves probability-weighted peak sales for Genmab's wholly owned ADC pipeline.
    Impact
    Platinum-resistant ovarian cancer represents a difficult oncology indication with limited standard-of-care options. An ORR of 45.9% combined with a 9.5-month median PFS establishes competitive efficacy for Genmab's topoisomerase I ADC platform. These clinical results provide regulatory derisking ahead of potential pivotal Phase 3 study designs and commercial partnering discussions.
    Affected
    GMAB
    Transmission
    A 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer improves probability-weighted peak sales for Genmab's wholly owned ADC pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABvaluation expansion via clinical derisking of wholly owned ADC candidateUp1-5dRina-S demonstrated 45.9% ORR and 9.5 month median PFS in platinum-resistant ovarian cancer.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month